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Aim  To  analyze  and  interpret  incidence  and  mortality 
trends of breast and ovarian cancers and incidence trends 
of cervical and endometrial cancers in Croatia for the pe-
riod 1988-2008.
Methods Incidence data were obtained from the Croatian 
National Cancer Registry. Themortality data were obtained 
from the World Health Organization (WHO) mortality data-
base. Trends of incidence and mortality were analysed by 
joinpoint regression analysis.
Results Joinpoint analysis showed an increase in the inci-
dence of breast cancer with estimated annual percent of 
change (EAPC) of 2.6% (95% confidence interval [CI], 1.9 to 
3.4). The mortality rate was stable, with the EAPC of 0.3%. 
Endometrial cancer showed an increasing incidence trend, 
with EAPC of 0.8% (95% CI, 0.2 to 1.4), while cervical cancer 
showed a decreasing incidence trend, with EAPC of -1.0 
(95% CI, -1.6 to -0.4). Ovarian cancer incidence showed 
three  trends,  but  the  average  annual  percent  change 
(AAPC) for the overall period was not significant, with a sta-
ble trend of 0.1%. Ovarian cancer mortality was increasing 
since 1992, with EAPC of 1.2% (95% CI, 0.4 to 1.9), while the 
trend for overall period was stable with AAPC 0.1%.
Conclusion Incidence trends of breast, endometrial, and 
ovarian  cancers  in  Croatia  1988-2008  are  similar  to  the 
trends observed in most of the European countries, while 
the modest decline in cervical cancer incidence and lack 
of decline in breast cancer mortality suggest suboptimal 
cancer prevention and control.
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Breast and gynecological cancers are among the seven 
most common female cancers in Croatia: in 2008 breast 
cancer was the most common cancer with the propor-
tion of 26% of all cancer sites, endometrial cancer ranked 
fourth (6%), ovarian cancer (with fallopian tubes cancer) 
sixth (5%), and cervical cancer seventh (4%) (1).
Breast, endometrial, and ovarian cancers share some simi-
lar risk factors like early menarche, late menopause, obesi-
ty, and low parity (2-5). Also, breast cancer in personal his-
tory increases the risk of endometrial and ovarian cancer 
(6). Delayed childbearing increases the risk of breast can-
cer but seems to have no impact on the development of 
ovarian and endometrial cancer (3-5). Diabetes mellitus in-
creases the risk of endometrial and breast cancer (7,8). Use 
of tamoxifen or other selective estrogen receptor modula-
tors increases the risk of endometrial and ovarian cancer, 
while the use of combined oral contraceptives is a pro-
tective factor (2,9,10). Also, tobacco smoking and alcohol 
intake reduce the risk of endometrial cancer (2,11,12). Al-
cohol intake and both oral contraceptives and hormon-
al replacement therapy are risk factors for breast cancer 
(2,13,14).  Multiparty  and  physical  activity  are  protective 
factors for all three cancers (2,4,15,16). Low socioeconomic 
status, sexually transmitted diseases, promiscuity, unpro-
tected sexual behavior, earlier age of first intercourse, and 
smoking are risk factors for cervical cancer (2,17-23). Infec-
tion with human papillomavirus is considered as a neces-
sary cause of cervical cancer (24).
The aim of this study was to report the incidence and mor-
tality of breast and ovarian cancers and incidence of en-
dometrial and cervical cancers, analyze the trends in the 




Incidence data for the period 1988-2008 were obtained 
from the Croatian National Cancer Registry. The Registry, 
founded in 1959, covers the whole Croatian population 
(approximately 4.4 million persons) and relies on man-
datory cancer notifications from primary and secondary 
health care sources and death certificates from the Cro-
atian Bureau of Statistics. The Registry contributed data 
to the last three volumes of the Cancer Incidence in Five 
Continents series (25-27). Breast cancer was classified in 
the International Classification of Diseases as ICD-10 C50 
and ICD-9 174, endometrial cancer as ICD-10 C54 and 
ICD-9 182, cervical cancer as ICD-10 C53 and ICD-9 180, 
and ovarian cancer as ICD-10 C56 and ICD-9 183. More 
than 95% of uterine corpus cancers are endometrial so 
we referred to all of them as endometrial cancer. The 
number of breast and ovarian cancer deaths were ob-
tained from the World Health Organization (WHO) mor-
tality database (28). Due to the frequent assignment of 
“malignant neoplasm of uterus, part unspecified” (ICD-10 
C55) as the underlying cause of death in the analyzed pe-
riod, and consequent underestimation of cervical and en-
dometrial cancer mortality, we did not include these data 
in the analysis (28).
statistical analysis
Age-standardized rates (ASR) of cancer incidence and mor-
tality were calculated by the direct standardization meth-
od, using the world standard population as a reference 
(29). To calculate age-specific incidence and mortality rates 
for breast cancer, we used the United Nations population 
estimates (30).
To describe incidence and mortality trends by calendar 
period, we carried out joinpoint regression analysis using 
the software Joinpoint Regression Program, Version 3.5.2, 
October 2011 (31). The analysis included the logarithmic 
transformation of the rates, standard error, maximum num-
ber of five joinpoints, and minimum of four years between 
two joinpoints. All other program parameters were set to 
default values. The aim of the approach is to identify pos-
sible joinpoints where a significant change in the trend oc-
curs. The method identifies joinpoints based on regression 
models with 0-5 joinpoints. The final model selected was 
the most parsimonious of these, with the estimated annu-
al percent change (EAPC) based on the trend within each 
segment (31). To quantify the trend over a fixed number of 
the years, the average annual percent change (AAPC) was 
calculated. The AAPC is computed as a geometric weight-
ed average of the EAPC trend analysis, with the weights 
equal to the lengths of each segment during the prespeci-
fied fixed interval.
In describing trends, the terms “significant increase” or “sig-
nificant decrease” signify that the slope of the trend was 
statistically significant (P < 0.05). For non-significant trends 
(P > 0.05), we used the terms “stable” (for EAPC between 
-0.5% and 0.5%), “non-statistically significant increase” (for 
EAPC>0.5%), and “non-statistically significant decrease” 




From  1988  to  2008,  the  number  of  new  breast  cancer 
cases increased from 1220 to 2472 and ASR of incidence 
increased from 35.5 to 61.9 per 100 000. The number of 
deaths increased from 670 to 902, while ASRs remained 
stable (Table 1).
Joinpoint analysis of incidence showed a significantly in-
creasing trend, with EAPC of 2.6% (95% confidence interval 
[CI], 1.9 to 3.4). Mortality trend was stable, with EAPC of -0.3% 
(95% CI, -0.6 to 0.0) (Table 2, Figure 1). When analyzed by 10-
year age groups (Table 2), the incidence was increasing in 
all age groups. A significant change in the incidence trend 
was most pronounced in 2005 in the 60-69 age group, with 
EAPC of 14.2% in the period 2005-2008.. Mortality decreased 
in younger age groups (30-49 years) and increased in older 
age groups (>60 years). In the age group 50-59 years, there 
was a change in trend starting from 1999. In that age group, 
mortality was increasing (EAPC 1.7%) from 1988 to 1999, 
when it started to decrease (EAPC -3.5%).
endometrial cancer
In 1988 there were 390, and in 2008 520 new cases of en-
dometrial cancer. The ASRs increased from 10.7/100 000 in 
1988 to 11.4/100 000 in 2008 (Table 3). Joinpoint analysis 
revealed a constant and significant increase, with the EAPC 
of 0.8% (95% CI, 0.2 to 1.4) for the period of 20 years (Table 
4, Figure 2).
ovarian cancer
The number of new ovarian cancer cases increased from 
337 in 1988 to 439 in 2008 (Table 3). Trend analysis of ovar-
ian cancer incidence showed three trends (Figure 3, Table 
FIgure 1. Joinpoint analysis of incidence and mortality of breast cancer 
in Croatia, 1988-2008. rhomb – incidence; triangle – mortality; Asr (W) – 
age-standardized rate per 100 000 (using world standard population).
FIgure 2. Joinpoint analysis of incidence of endometrial cancer in Croa-
tia, 1988-2008. Asr (W) – age-standardized rate per 100 000 (using world 
standard population).
TABle 1. Breast cancer incidence and mortality data, Croatia 
1988-2008. number of cases, crude rate, and age standardized 
rate (Asr) per 100 000 (using world standard population)
Incidence Mortality
Year n crude rate Asr n crude rate Asr
1988 1220   52.7 35.5 670 28.9 18.0
1989 1353   58.3 38.8 661 28.5 17.8
1990 1461   62.7 40.7 710 30.5 18.4
1991 1351   57.5 37.9 758 32.3 19.8
1992 1429   60.3 37.7 730 30.8 18.0
1993 1539   64.3 40.6 758 31.7 18.4
1994 1658   68.7 43.6 749 31.1 17.7
1995 1779   73.6 45.4 768 31.8 18.0
1996 1782   73.8 45.8 706 29.3 16.9
1997 1883   78.6 47.7 769 32.1 17.8
1998 1908   80.3 47.8 794 33.4 18.4
1999 2544 108.1 67.4 856 36.4 19.7
2000 2038   87.3 51.7 843 36.1 18.5
2001 2233   96.1 57.0 832 35.8 18.5
2002 2052   88.6 51.1 804 34.7 17.1
2003 2251   97.4 55.8 822 35.6 16.9
2004 2164   93.8 52.8 825 35.8 17.9
2005 2303 100.0 56.2 922 40.0 18.0
2006 2205   95.9 54.3 830 36.1 17.1
2007 2574 112.1 62.7 861 37.5 17.3
2008 2472 107.9 61.9 902 39.4 17.6103 Kelava et al: Breast and gynecological cancers in Croatia
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4). Changes in the trend occurred in 1997 and 2000. Be-
tween 1988 and 1997, the trend was stable, with EAPC 0.4% 
(95% CI, -1.2 to 1.9). Between 1997 and 2000, there was a 
non-significant increase in incidence, with EAPC 8.1% (95% 
CI, -7.4 to 26.2). Between 2000 and 2008, there was a signifi-
cant decreasing incidence, with EAPC -3.1% (95% CI, -4.8 to 
-1.4) (Table 4). AAPC for the overall period was not signifi-
cant, with a stable trend of 0.1% (95% CI, -2.2 to 2.4).
TABle 2. Joinpoint analysis of breast cancer incidence and mortality in Croatia, 1988-2008 with the estimated annual percent 
change (eAPC) and 95% confidence intervals (CI)
Trend 1 (years) eAPC (95% CI) Trend 2 (years) eAPC (95% CI)
Incidence by age-group:
30-39 1988-2008  1.1 (-0.5 to 2.8)
40-49 1988-2008  1.7* (0.6 to 2.7)
50-59 1988-1999  6.2* (4.9 to 7.6) 1999-2008   0 (-1.6 to 1.8)
60-69 1988-2005  3.0* (2.2 to 3.9) 2005-2008 14.2* (1.7 to 28.3)
70-79 1988-1999  3.5* (2.4 to 4.7) 1999-2008 -0.1 (-1.7 to 1.4)
>80 1988-2003  2.7* (1.5 to 3.8) 2003-2008 -3.4 (-8.9 to 2.3)
Overall 1988-2008  2.6* (1.9 to 3.4)
Mortality by age-group:
30-39 1988-2008 -3.2* (-4.8 to -1.5)
40-49 1988-2008 -1.5* (-2.5 to -0.5)
50-59 1988-1999  1.7* (0.4 to 3.1) 1999-2008 -3.5* (-5.3 to -1.7)
60-69 1988-2008  0.3 (-0.3 to 0.9)
70-79 1988-2008  0.2 (-0.5 to 1)
>80 1988-2008  1.6* (0.9 to 2.3)
Overall 1988-2008 -0.3 (-0.6 to 0)
*statistically significant trend.
TABle 3. gynecological cancer incidence and mortality data, Croatia 1988-2008. number of cases, crude rate, and age standardized 
rate (Asr) per 100 000 (using world standard population)
Cervical cancer incidence endometrial cancer incidence ovarian cancer incidence ovarian cancer mortality
Year n crude rate Asr n crude rate Asr n crude rate Asr n crude rate Asr
1988 406 17.5 12.2 390 16.8 10.7 337 14.6 9.8 230   9.93 6.60
1989 429 18.5 13.3 382 16.5 10.1 372 16.0 10.8 220   9.48 5.87
1990 399 17.1 11.9 391 16.8 10.4 393 16.9 11.3 239 10.25 6.28
1991 340 14.5 10.3 357 15.2 9  .3 361 15.4   9.9 227   9.66 5.65
1992 375 15.8 11.0 389 16.4 10.0 390 16.4 10.6 205   8.64 5.31
1993 415 17.3 12.5 403 16.8 10.3 397 16.6 10.8 243 10.15 5.95
1994 405 16.8 12.0 414 17.2   9.9 383 15.9 10.7 229   9.49 5.86
1995 416 17.2 11.9 469 19.4 11.2 427 17.7 11.1 212   8.76 5.01
1996 365 15.1 10.5 511 21.2 11.9 418 17.3 10.5 239   9.90 5.55
1997 394 16.4 11.2 528 22.0 12.2 419 17.5 10.9 241 10.05 5.56
1998 358 15.1 10.2 475 20.0 10.9 426 17.9 10.7 255 10.74 5.88
1999 403 17.1 11.4 578 24.6 13.3 537 22.8 13.8 279 11.86 6.27
2000 426 18.2 12.7 508 21.8 11.9 550 23.6 14.5 267 11.43 6.01
2001 320 13.8   9.7 477 20.5 10.8 516 22.2 13.1 311 13.39 6.90
2002 363 15.7 10.7 488 21.1 11.0 489 21.1 12.1 289 12.48 6.37
2003 314 13.6   9.1 471 20.4 10.6 466 20.2 11.7 275 11.90 5.97
2004 330 14.3   9.8 509 22.1 11.3 432 18.7 10.7 278 12.05 6.15
2005 320 13.9   9.4 479 20.8 10.9 490 21.3 12.2 287 12.46 5.94
2006 345 15.0 10.4 534 23.2 12.0 450 19.6 11.1 291 12.66 6.16
2007 387 16.9 11.3 572 24.9 12.7 468 20.4 12.0 299 13.03 6.42
2008 359 15.7 10.2 520 22.7 11.4 439 19.2 10.5 326 14.23 7.09CANCER EPIDEMIOLOGY  104 Croat Med J. 2012;53:100-8
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Joinpoint analysis of ovarian cancer mortality revealed two 
trends. Trend 1 showed a non-significant decrease, with 
EAPC -4.12% (95% CI, -10.2 to 2.3). Trend 2 showed a signifi-
cant increase of EAPC 1.2% (95% CI, 0.4 to 1.2%). AAPC for 
the overall period was not significant, with a stable trend of 
0.1% (95% CI, -1.2 to 1.4).
Cervical cancer
In the period 1988-2008, the number of new cervical can-
cer cases decreased from 406 to 359, or with ASR of 16% 
– from 12.2/100 000 to 10.2/100 000 (Table 3). Joinpoint 
trend analysis showed a decrease in the incidence with a 
significant annual change of -1.0%, (95% CI, -1.6 to -0.4) (Ta-
ble 4, Figure 4).
dIsCussIon
Breast cancer
According  to  our  results  and  GLOBOCAN  estimates  for 
2008 (32), Croatia is among the European countries with 
an  intermediate  breast  cancer  incidence  and  mortality. 
The  increasing  incidence  trend  in  Croatia  1988-2008  is 
comparable to trends in other European countries. Thirty-
five countries with Caucasian majority population showed 
an increase in the incidence of breast cancer in the period 
1990-2002, particularly in Central and Eastern European 
countries. The increase was slightly higher in the countries 
with initially lower incidence (33).
Possible explanations for the increase in the incidence in 
Croatia are a higher prevalence of lifestyle-associated risk 
factors and improvements in diagnostics. For example, pro-
portion of overweight women increased from 42.9% in 1997 
to 58.2% in 2003, the average age at first birth increased 
from 23.5 years in 1960 to 27.4 years in 2009, and the fertility 
rate decreased from 2.9 in 1950 to 1.5 in 2009 (34,35). Also, 
the increase may have been affected by a higher prevalence 
of alcohol consumption and the use of hormonal replace-
ment therapy and oral contraceptives. The use of hormonal 
replacement therapy and oral contraceptives in Croatia is 
lower than in most European countries, but average alcohol 
intake is among the highest in Europe (36-38).
FIgure 3. Joinpoint analysis of incidence and mortality of ovarian cancer 
in Croatia, 1988-2008. rhomb – incidence; triangle – mortality; Asr (W) – 
age-standardized rate per 100 000 (using world standard population).
FIgure 4. Joinpoint analysis of incidence of cervical cancer in Croatia, 
1988-2008. Asr (W) – age-standardized rate per 100 000 (using world 
standard population).
TABle 4. Joinpoint analyses of gynecological cancers incidence 
and mortality in Croatia, 1988-2008, with the estimated annual 










1 1988 2008 -1.0* (-1.6 to -0.4)
endometrial cancer 
incidence
1 1988 2008  0.8* (0.2 to 1.4)
ovarian cancer 
incidence
1 1988 1997  0.4 (-1.2 to 1.9)
2 1997 2000  8.1 (-7.4 to 26.2)
3 2000 2008 -3.1* (-4.8 to -1.4)
ovarian cancer 
mortality
1 1988 1992 -4.1 (-10.2 to 2.3)
2 1992 2008  1.2* (0.4 to 1.9)
*statistically significant trend.105 Kelava et al: Breast and gynecological cancers in Croatia
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Croatian  national  breast  cancer  screening  programme 
“Mamma” was introduced in 2006. It includes women aged 
50-69 years. In the first screening cycle, 720 982 women 
were  invited  to  mammography  screening,  with  the  re-
sponse of 63% and more than 1500 detected breast can-
cers (39). The national screening program could have af-
fected the increase in the incidence that appeared in the 
age group 60-69 years after 2005. However, the lack of sim-
ilar increase in the age group 50-59 years does not confirm 
this hypothesis.
Besides its influence on the incidence, the national screen-
ing program is also expected to reduce mortality. Coun-
tries with long-standing breast cancer screening program 
had reduced mortality in the screened population (40-42). 
However, the screening-related reduction in mortality is 
expected to occur in Croatia in the next 5-10 years (40-42).
Interestingly, in some countries the decline in breast can-
cer mortality had started before screening was introduced 
and occurred in non-screened population. Also, declines 
in mortality were also observed in countries without na-
tional screening programs (42). Similarly, the highest de-
cline in mortality in our study was found in younger age 
groups. Also the decrease in mortality in the age-group 
50-59 years started in 1999, before the introduction of the 
screening program, which could probably be attributed to 
improved breast cancer care.
endometrial and ovarian cancer
Gynecological cancers in different European countries ex-
hibit very different incidence trends. A study of geographic 
and temporal variations of endometrial cancer incidence 
in 13 European countries in the period from 1964 to 2000 
(43) found increasing trends in Iceland, the Netherlands, 
Czech Republic, Slovakia, Slovenia, Finland, Norway, Swe-
den, United Kingdom, Spain, and Poland with EAPCs from 
0.8 to 3.4% for menopausal women. Decreasing incidence 
trends were reported for Italy, Switzerland, and Denmark, 
with EAPCs from -0.8 to -1.1%, while Germany had stable 
incidence. The increasing incidence trend of endometrial 
cancer in Croatia with EAPC of 0.8% is similar to most of the 
European countries.
According to GLOBOCAN 2008 estimates, Croatia is among 
the  20  countries  in  Europe  with  the  highest  incidence 
of ovarian cancer (32). The countries that had a high in-
cidence of ovarian cancer in 1960s and 1970s, like Nordic 
countries, Austria, Germany, and United Kingdom, nowa-
days show a declining incidence, while Southern and East-
ern European countries show an increasing incidence (44). 
Our trend analysis for Croatia showed a stable incidence 
trend, with AAPC of 0.1%.
Increasing endometrial cancer incidence and high ovar-
ian cancer incidence in Croatia could be explained by an 
increasing prevalence of factors such as obesity and low 
parity. Growing obesity is an important public health prob-
lem. A recent study reported that 34% Croatian women are 
overweight (45). Another risk factor for endometrial cancer 
is diabetes mellitus, the total prevalence of which in adults 
in Croatia is high (8.9%) and growing (46). At the same time, 
oral contraception, which was associated with a decreased 
risk for endometrial and ovarian cancer, is rarely used (37). 
However, a significant decrease in the incidence of ovar-
ian cancer in the period 2000-2008 could possibly be ex-
plained by an increased use of oral contraception since 
1980s, but there are no scientific data to corroborate it. This 
decreasing incidence trend has not yet reflected on mor-
tality, which has had a significantly increasing trend since 
1992, with EAPC of 1.2%, in contrast to the trends observed 
in most of the other European populations (44). Also, the 
ASR remains high, placing Croatia among the countries 
with the highest ovarian cancer mortality in Europe (32).
Cervical cancer
According to GLOBOCAN 2008 estimates, Croatia has an 
intermediate ASR of cervical cancer (32). From the mid-
dle 1990s to early 2000s, the rates of cervical cancer were 
highest in Central Europe, the lowest in Finland, Italy, and 
Malta, and stable in Nordic countries, Ireland, Austria, and 
the Netherlands (47). The largest decrease in incidence was 
observed in countries with organized screening programs 
like Finland and the Netherlands (48).
The introduction of the Pap smear, which detects prema-
lignant lesions of the cervix and early stages of cervical 
cancer, reduced the incidence and mortality in developed 
countries (49). In Croatia, Pap smears were introduced in 
1950s (50) and became part of the routine gynecologi-
cal examination. This led to a decrease in incidence, but 
an even greater decrease could be achieved through an 
organized screening program. The Finnish model of orga-
nized Pap screening program shows to which extent it is 
possible to decrease cervical cancer incidence (51). In ad-
dition to an 80% reduction in cervical cancer incidence 
in the age-group 30-64 years, which can be achieved 
by organized screening (51), further decrease could CANCER EPIDEMIOLOGY  106 Croat Med J. 2012;53:100-8
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be achieved by the use of HPV vaccines against oncogen-
ic types (52). HPV vaccines have been available in Croatia 
since 2007, but vaccination is not obligatory (53). HPV vac-
cines cannot replace cytological screening for cervical can-
cer and their influence on cervical cancer incidence is yet 
to be seen (54). Croatia already has screening programs for 
breast and colorectal cancers (39) and the introduction of 
a screening program for cervical cancer is planned for the 
near future. However, more investment in cancer preven-
tion is needed, in terms of reducing the exposure to highly 
prevalent lifestyle risk factors and maintaining or introduc-
ing high-quality national screening programs for breast 
and cervical cancers.
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